Basel, 20 November 2017 Roche’s Hemlibra significantly reduced bleeds in phase III study in haemophilia A HAVEN 3 study met primary endpoint and key secondary endpoints Intra-patient comparison demonstrated superiority of Hemlibra prophylaxis compared to prior factor VIII prophylaxis Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III HAVEN 3... Read more
Basel, 20 November 2017 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA)... Read more
Basel, 20 November 2017 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA)... Read more
Basel, 17 November 2017 Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain The Viewics solution allows for efficient integration of big data from a variety of IT systems in the laboratory and beyond, pioneering a new way in extracting, cleansing, transforming and... Read more
Basel, 17 November 2017 FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma The first treatment option to demonstrate superior progression-free survival over standard-of-care Rituxan-based therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in... Read more
Basel, 16 November 2017 FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors First new medicine in nearly 20 years to treat people with haemophilia A with inhibitors Hemlibra substantially reduced bleeds in adults and children Only medicine that can be self-administered once weekly by injection under the skin (subcutaneously) Roche (SIX: RO, ROG;... Read more
– Kit expands multiplexing options, allowing more biomarkers to be investigated on a single tissue slide – Multiplexed assays for simultaneously detecting several biomarkers in a single sample address growing need to obtain more information from limited tissue samples TUCSON, Arizona, Nov. 16, 2017 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the... Read more
Basel, 10 November 2017 Roche’s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis If approved, OCREVUS will be an important treatment option for people with active relapsing forms of multiple sclerosis (RMS) showing superior efficacy on three major markers of disease activity and disability progression compared... Read more
Basel, 07 November 2017 FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche (SIX: RO, ROG; OTCQX: RHHBY) announced... Read more
Basel, 07 November 2017 FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Approval based on phase III results that showed Alecensa extended the average time that people lived without their disease worsening compared to crizotinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food... Read more